Japan plays a critical role in the global pricing landscape, particularly as evolving US pricing policies continue to influence international reference pricing (IRP) discussions.
Watch our recording to explore Japan’s Pricing & Market Access (P&MA) environment in the context of the US Most Favored Nation (MFN) policy. Simon-Kucher experts discuss recent policy developments, pricing and reimbursement outcomes for innovative medicines, and strategies for optimizing launch pricing while supporting global pricing objectives.
Participants learn:
- How Japan's drug prices could affect global pricing through international reference pricing (IRP) under MFN
- How Japan's P&MA environment has responded to MFN, including payer and industry perspectives and recent policy changes
- Recent pricing and reimbursement outcomes for innovative medicines in Japan and the factors shaping those results
- How pharmaceutical and biotech companies optimize launch pricing and maximize value within Japan’s evolving pricing framework
